Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Are You Positioned To Capitalize When History Is Made

Apr 10, 2017 • 12:02 PM EDT
Untitled design (85).png
5 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Canada is set to make history this week by considering legislation to become the first G-7 country to legalize recreational cannabis.

This development has captured the attention of the market and many investors are focusing on companies levered to this opportunity. We want to highlight three companies that investors should be closely monitored.

Canabo Announces Groundbreaking Results

On Friday, Canabo Medical (CMM.V: TSX Venture) (CAMDF: OTCQB) released the results of an observational study that connected doctor-supervised medical cannabis treatments to a decrease in benzodiazepine reliance among Canadian patients. The team responsible for the report shared its findings with several Canadian medical journals and details are expected to be published in the Dalhousie Medical Journal.

This announcement came after Canabo Executive Chairman Dr. Neil Smith reported the findings during a presentation at the Canadian Consortium for the Investigation of Cannabinoids event in Toronto.

Research conducted over the past year revealed that 40% of patients who were prescribed medical cannabis to treat pain and anxiety eliminated the use of benzodiazepines within 90 days. The number of patients who stopped using benzodiazepines increased to 45% within a year of cannabis treatment.

Canabo has also been collecting data related to the extent cannabis serves as a substitute or an effective complement to traditional opioid therapies. Friday’s report is expected to be the first in a series that examines the role of cannabis in modern therapies.

Horizon’s Cannabis ETF Rallies During First Week

Horizons Medical Marijuana Life Sciences ETF commenced trading on the Toronto Stock Exchange (TSX) last week under the ticker symbol HMMJ and it’s up more than 7% since then.

The Medical Marijuana Life Sciences ETF is designed to be a liquid and investable index of publicly listed life sciences companies and other firms focused on the cannabis industry. The index selects from a universe of publicly-listed North American companies that have operations that may include one or more of the following: biopharmaceuticals, medical manufacturing, distribution, bio-products and other ancillary businesses within the cannabis industry.

The index only includes stocks that meet minimum asset and liquidity thresholds. The index is rebalanced quarterly on a market-capitalization basis and capped so that no single stock can exceed 10% of the portfolio’s weight when rebalanced. As of March 20th, the fund planned to allocate as such: 

  • Scotts Miracle Gro (SMG): 10%
  • GW Pharma (GWPH): 10%
  • Insys Therapeutics (INSY): 10%
  • Canopy Growth (WEED.TO) (TWMJF): 10%
  • Aurora Cannabis (ACB.V) (ACBFF): 10%
  • Aphira (APH.TO) (APHQF): 10%
  • Cronos (MJN.V) (PRMCF): 7.41%
  • Zynerba Pharma (ZYNE): 7.15%
  • Cannimed (CMED.TO) (CMMDF): 5.04%
  • Supreme (SL.CN) (SPRWF): 3.95%
  • Emblem (EMC.V) (EMMBF): 3.8%
  • CannaRoyalty (CRZ.CN) (CNNRF): 2.61%
  • Emerald Health (EMH.V) (TBQBF): 2.01%
  • ICC International Cannabis (ICC) (ICCLF): 1.89%
  • Maple Leaf Green World (MGV) (MGWFF): 1.66%

Lexaria and Neutrisci Move Partnership Forward

Today, Lexaria Bioscience Corp (LXRP: OTCQB) (LXX.CN: CSE) and Neutrisci International (NU.V: TSX Venture) (NRXCF: OTCQB) executed its previously announced joint venture to produce and commercialize a line of edible cannabinoid mouth-melt products. The products will utilize Lexaria’s patented technology and Neutrisci’s proprietary pterostilbene tablet form factor.

The joint venture will operate under the name Ambarii Trade Corporation and initial operations will be equally funded by the companies. Lexaria and Neutrisci will contribute their respective technologies through a license agreement and will share profits derived from the JV on a 50/50 basis.

Ambarii intends to secure licensees in California, Colorado and in Canada to manufacture and sell mouth-melt products containing THC. These products will combine the benefits of each of Lexaria’s and Neutrisci’s existing technologies and ingredient mixes. In June, a licensed California entity is scheduled to manufacture and test a THC version of the products.

Ambarii also intends to develop hemp oil-based products for distribution through networks including Neutrisci’s existing network of retail distributors as well as other methods. Initial production runs on these products have already achieved positive results in a human focus group.

This joint venture is attractive and may provide an avenue to create value for shareholders of both companies. Although there are no immediate plans to do so, Ambarii will be structured to allow for a potential future spin-off in the form of a stock dividend,

Become a Mushroomstocks Premium Member to learn more! 



Important Investor Disclosures 

Disclosure.  Compensated Affiliate.  This report was authored by and is property of Mushroomstocks.  All information and data relied upon in drafting this report is publicly available.  The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by Mushroomstocks regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional advice regarding any and all securities investments.  This report is intended for informational purposes only.  Mushroomstocks’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by Mushroomstocks.  Mushroomstocks may receive compensation from the company and/or has a position in the securities mentioned in this report

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.